Table 1.
Clinicopathologic analysis of breast cancer patients
| Frequency | Percent | |
|---|---|---|
| Age | ||
| < 40 | 3/81 | 3.7 |
| 40–50 | 14/81 | 17.3 |
| 51–60 | 24/81 | 29.6 |
| > 60 | 40/81 | 49.4 |
| Histologic type | ||
| IC NST | 60/81 | 74.1 |
| ILC | 13/81 | 16.0 |
| SS | 8/81 | 9.9 |
| Tumor stage | ||
| I–IIA | 32/67 | 47.8 |
| IIB–III | 27/67 | 40.3 |
| IV | 8/67 | 11.9 |
| Tumor grade | ||
| 1 | 8/67 | 11.9 |
| 2 | 21/67 | 31.3 |
| 3 | 38/67 | 56.7 |
| PR positive | 59/73 | 80.8 |
| PRA-H | 35/57 | 61.4 |
| PRB-H | 18/57 | 31.6 |
| EQUI | 4/57 | 7.0 |
| ERα positive | 63/74 | 85.1 |
| HER2 positive | 11/75 | 14.7 |
| Triple negative | 7/68 | 10.3 |
IC NST invasive carcinoma of no special type, ILC invasive lobular carcinoma, SS special subtype, PR progesterone receptor, PRA-H tumors with high PRA/PRB ratios, PRB-H tumors with low PRA/PRB ratios, EQUI tumors with equal levels of isoforms A and B of PR, ERα estrogen receptor alpha